TCR2 Therapeutics (TCRR) to Offer 6M Common Shares
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/1/2026
- Wall Street ends lower as higher yields, rising oil prices mark shaky start to September
- Oil prices jump 4% as fresh US-Iran fighting stokes supply fears
- Two Saudi tankers struck in Strait of Hormuz Monday
- Dell again lifts annual forecasts as AI demand powers record results
- Fed’s Barr backs rate hike if inflation fails to cool, September odds hit 66%
TCR² Therapeutics Announces Proposed Public Offering of Common Stock
July 27, 2020 4:01 PM EDTCAMBRIDGE, Mass., July 27, 2020 (GLOBE NEWSWIRE) -- TCR2 Therapeutics Inc. (Nasdaq: TCRR) (TCR2 or the Company), a clinical-stage immunotherapy company with a pipeline of novel T cell therapies for patients suffering from cancer, today announced that it has commenced an underwritten public offering of 6,000,000 shares of its common stock. TCR2 also intends to grant the underwriters a 30-day option to purchase up to an additional 900,000 shares of common stock. All of the shares in the proposed offering are to be sold by TCR2. The proposed offering is subject to market and other... More
